Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib and Binimetinib in Advanced Melanoma
NCT04741997Phase 1Recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- May 2021
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of encorafenib, binimetinib and nivolumab in melanoma (4 arms), sponsored by Moffitt Cancer Center. Primary endpoint: Rate of Disease Relapse at 24 weeks. Started May 2021; status: recruiting.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04741997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04741997.